drugset / Trial / NCT00862303

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma

NCT00862303

Phase 1/2 Unknown 100 enrolled Fuzhou General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.

Timeline

Start
2009-03
Primary completion
2015-06
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CIK cells Cell therapy
Subject DC vaccine Vaccine Other
Comparator IFN-α Unknown
Comparator aldesleukin Protein / enzyme biologic

Indications